Market Overview

Inovio's Manufacturing, Scalability Concerns Of Coronavirus Vaccine Keeps This Analyst On The Sidelines

Share:
Inovio's Manufacturing, Scalability Concerns Of Coronavirus Vaccine Keeps This Analyst On The Sidelines

Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Tuesday interim Phase 1 readout for INO-4800, its DNA vaccine candidate against the novel coronavirus.

The Inovio Analyst: Piper Sandler analyst Christopher Raymond maintained a Neutral rating and $8 price target for Inovio.

The Inovio Thesis: There wasn't a ton of detail at this point from the readout except that 94% or 34 of the 36 patients, demonstrating an "overall immunological" response at week 6, with a benign safety profile, Raymond said in a note. This appeared consistent with preclinical data published in May.

Raymond, however, said he would like to see data on neutralizing antibody production and T cell response generation separately and broken out by dose before drawing too many conclusions.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

The analyst expressed satisfaction with the safety data reported by Inovio.

"While initial human immunogenicity data is a necessary first step toward a viable COVID-19 vaccine, at this stage it's difficult (if not impossible) to determine which development candidate(s) will fare best in large-scale clinical trials," Raymond wrote in the note.

An equally important consideration is scalability.

The analyst is concerned over Inovio's dispute with its longtime manufacturing partner VGXI.

Investor hopes for INO-4800 to emerge as a viable vaccine candidate to address the current COVID-19 pandemic could prove unrealistic, barring clarity on the manufacturing scalability front, the analyst said.

Inovio Price Action: Inovio shares tumbled 14.9% to $26.95.

Latest Ratings for INO

DateFirmActionFromTo
Sep 2020Cantor FitzgeraldDowngradesOverweightNeutral
Sep 2020Maxim GroupUpgradesHoldBuy
Jul 2020Maxim GroupDowngradesBuyHold

View More Analyst Ratings for INO
View the Latest Analyst Ratings

 

Related Articles (INO)

View Comments and Join the Discussion!

Posted-In: Christopher Raymond CoronavirusAnalyst Color Biotech Health Care Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
HUMPiper SandlerMaintains495.0
HTBKPiper SandlerMaintains8.0
HOPEPiper SandlerMaintains8.0
HAFCPiper SandlerMaintains9.0
GBCIPiper SandlerMaintains36.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com